Fig. 1From: GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologiesa GAD65Ab titers in patients with SPS, T1D, and epilepsy. GAD65Ab titers were determined for all patients in RBA and are reported for SPS patients (n = 20) (open diamonds), T1D patients (n = 42) (open circles), and patients diagnosed with epilepsy (n = 38) (triangles). In the epilepsy group, patients diagnosed with both T1D and epilepsy (n = 10) are shown as filled triangles, while patients diagnosed with epilepsy only are shown as open triangles. Individual patient titers and median binding for each group are shown. Significant differences in GAD65Ab titers are indicated by horizontal bars. b GAD65 enzyme activity inhibition by patients’ sera. GAD65 enzymatic activity in the presence of patients’ sera was determined for SPS patients (n = 20) (open diamonds), T1D patients (n = 42) (open circles), and patients diagnosed with epilepsy (n = 38) (triangles). In the epilepsy group, patients diagnosed with both T1D and epilepsy (n = 10) are shown as filled triangles, while patients diagnosed with epilepsy only are shown as open triangles. GAD65 enzyme activity is presented as remaining activity, related to un-inhibited activity (set at 100%). Individual patient data and median enzyme activity are shown. Significant differences in GAD65 enzyme activity are indicated by the horizontal barBack to article page